These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35606883)

  • 1. Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial.
    Na HR; Kwon OS; Kang JK; Kim YH; Lim JY
    Trials; 2022 May; 23(1):430. PubMed ID: 35606883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study).
    Wang YW; Xu J; Ma L; Hu H; Chen HW; Hua JS; Kong XY; Li D; Li LW; Pan JY; Wu J
    BMJ Open; 2024 Jul; 14(7):e083730. PubMed ID: 39009458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Perioperative Use of Evolocumab in Myocardial Infarction Patients: Study Protocol for a Multicentre Randomized Controlled Trial.
    Luan Y; Wang M; Zhao L; Xu T; Fu G; Zhang W
    Adv Ther; 2021 Apr; 38(4):1801-1810. PubMed ID: 33638801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
    Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
    Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial.
    Liakopoulos OJ; Kuhn EW; Hellmich M; Kuhr K; Krause P; Reuter H; Thurat M; Choi YH; Wahlers T;
    Am Heart J; 2015 Jul; 170(1):46-54, 54.e1-2. PubMed ID: 26093863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
    Bohula EA; Marston NA; Ruzza A; Murphy SA; De Ferrari GM; Diaz R; Leiter LA; Elliott-Davey M; Wang H; Bhatia AK; Giugliano RP; Sabatine MS
    Am Heart J; 2024 Mar; 269():179-190. PubMed ID: 38160917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
    Murphy SA; Pedersen TR; Gaciong ZA; Ceska R; Ezhov MV; Connolly DL; Jukema JW; Toth K; Tikkanen MJ; Im K; Wiviott SD; Kurtz CE; Honarpour N; Giugliano RP; Keech AC; Sever PS; Sabatine MS
    JAMA Cardiol; 2019 Jul; 4(7):613-619. PubMed ID: 31116355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary artery bypass grafting in high-RISk patients randomised to off- or on-Pump surgery: a randomised controlled trial (the CRISP trial).
    Rogers CA; Pike K; Campbell H; Reeves BC; Angelini GD; Gray A; Altman DG; Miller H; Wells S; Taggart DP;
    Health Technol Assess; 2014 Jul; 18(44):v-xx, 1-157. PubMed ID: 25023641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
    Oyama K; Furtado RHM; Fagundes A; Zelniker TA; Tang M; Kuder J; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
    J Am Coll Cardiol; 2021 Jan; 77(3):259-267. PubMed ID: 33197560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.
    Wiviott SD; Giugliano RP; Morrow DA; De Ferrari GM; Lewis BS; Huber K; Kuder JF; Murphy SA; Forni DM; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2020 Jul; 5(7):787-793. PubMed ID: 32347885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
    Furtado RHM; Fagundes AA; Oyama K; Zelniker TA; Tang M; Kuder JF; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
    Circ Cardiovasc Interv; 2022 Mar; 15(3):e011382. PubMed ID: 35209731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early tirofiban versus heparin for bridging dual antiplatelet therapy in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting: a multicenter randomized controlled trial protocol (the THACE-CABG trial).
    Chen L; Gao MX; Du X; Wang C; Yu WY; Liu HL; Ding XH; Wang BL; Zhang K; Xu D; Han Z; Xie BD; Dong R; Yu Y
    Trials; 2024 Jan; 25(1):52. PubMed ID: 38225640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.
    Head SJ; Milojevic M; Daemen J; Ahn JM; Boersma E; Christiansen EH; Domanski MJ; Farkouh ME; Flather M; Fuster V; Hlatky MA; Holm NR; Hueb WA; Kamalesh M; Kim YH; Mäkikallio T; Mohr FW; Papageorgiou G; Park SJ; Rodriguez AE; Sabik JF; Stables RH; Stone GW; Serruys PW; Kappetein AP
    J Am Coll Cardiol; 2018 Jul; 72(4):386-398. PubMed ID: 30025574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
    McClintick DJ; O'Donoghue ML; De Ferrari GM; Ferreira J; Ran X; Im K; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Atar D; Keech A; Giugliano RP; Sabatine MS
    J Am Coll Cardiol; 2024 Feb; 83(6):652-664. PubMed ID: 38325990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of direct cardiac shockwave therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial-an update.
    Nägele F; Pölzl L; Graber M; Hirsch J; Mayr A; Pamminger M; Troger F; Theurl M; Schreinlechner M; Sappler N; Dorfmüller C; Mitrovic M; Ulmer H; Grimm M; Gollmann-Tepeköylü C; Holfeld J
    Trials; 2022 Dec; 23(1):988. PubMed ID: 36494706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of remote ischemic preconditioning preceding coronary artery bypass grafting on inducing neuroprotection (RIPCAGE): study protocol for a randomized controlled trial.
    Gasparovic H; Kopjar T; Rados M; Anticevic A; Rados M; Malojcic B; Ivancan V; Fabijanic T; Cikes M; Milicic D; Gasparovic V; Biocina B
    Trials; 2014 Oct; 15():414. PubMed ID: 25348157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.
    Lee CW; Ahn JM; Cavalcante R; Sotomi Y; Onuma Y; Suwannasom P; Tenekecioglu E; Yun SC; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Serruys PW; Park SJ
    JACC Cardiovasc Interv; 2016 Dec; 9(24):2481-2489. PubMed ID: 28007199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin loading before coronary artery bypass grafting: a randomized trial.
    Liakopoulos OJ; Kuhn EW; Hellmich M; Schlömicher M; Strauch J; Reents W; Diegeler A; Thielmann M; Wendt D; Börgermann J; Gummert JF; Stoppe C; Goetzenich A; Martens S; Reichenspurner H; Wippermann J; Reuter H; Choi YH; Wahlers T;
    Eur Heart J; 2023 Jul; 44(25):2322-2331. PubMed ID: 37086268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
    ; Alexander JH; Emery RW; Carrier M; Ellis SJ; Mehta RH; Hasselblad V; Menasche P; Khalil A; Cote R; Bennett-Guerrero E; Mack MJ; Schuler G; Harrington RA; Tardif JC
    JAMA; 2008 Apr; 299(15):1777-87. PubMed ID: 18381567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF).
    Rezende PC; Hueb W; Bocchi EA; Farkouh M; Junior CVS; Lima EG; Silva EER; Dallan LAO; Gaiotto FA; Garzillo CL; Rochitte CE; Nomura CH; Scudeler TL; Soares PR; Jatene FB; Ramires JAF; Filho RK
    Trials; 2020 Apr; 21(1):337. PubMed ID: 32299458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.